Sanofi : A new building block in the development of a COVID-19 vaccine
>New agreement with an mRNA player - Sanofi just announced that it is starting a new collaboration with biotech Translate Bio. The agreement is aimed at developing a new mRNA candidate vaccine for COVID-19. This new agreement comes after an initial collaboration between the two players in 2018, which concerned five infectious pathogens and an option on other pathogens. The initial deal was worth $Â 805m in total. This new collaboration therefore arises from this i...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.